RC
NVCT icon

Ronit Capital’s Nuvectis Pharma NVCT Stock Holding History

Ronit Capital’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.99M Buy
562,547
+143,265
+34% +$1.33M 5.37% 4
2022
Q2 		$4.7M Sell
419,282
-130,718
-24% -$1.62M 6.66% 2
2022
Q1 		$4.08M Buy
+550,000
New +$3.83M 5.1% 7

Other funds holding NVCT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ronit Capital's NVCT Position: Q3 2022 in Review

Ronit Capital increased its Nuvectis Pharma (NVCT) stake by 34% in Q3 2022, buying an estimated $1.33M and bringing the position to 562,547 shares worth $3.99M. The position accounts for 5.37% of the portfolio, ranked #4.

Ronit Capital first reported a position in NVCT in Q1 2022 and has held it in 3 quarters since. The position peaked at $4.7M in Q2 2022. 12 funds tracked by Wall St. Rank hold NVCT as of Q3 2022.

  • Ronit Capital held 562,547 shares of Nuvectis Pharma worth $3.99M as of Q3 2022.
  • Ronit Capital bought 143,265 Nuvectis Pharma shares in Q3 2022, an estimated $1.33M.
  • Nuvectis Pharma made up 5.37% of Ronit Capital's portfolio in Q3 2022, its #4 holding.
  • Ronit Capital first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 3 quarters since.
  • Ronit Capital's Nuvectis Pharma position peaked at $4.7M in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2022.

Based on Ronit Capital's 13F filing for Q3 2022, filed 4 Nov 2022.